Reply
- 7 December 2024
- journal article
- Published by Elsevier in Gastroenterology
- Vol. 168 (3) , 633-634
Abstract
No abstract availableFunding Information
- Arrowhead Pharmaceuticals Inc
- Takeda Pharmaceuticals America Inc
This publication has 8 references indexed in Scilit:
- Fazirsiran Unveiled: Methodological Considerations for Optimizing Treatment in Alpha-1 Antitrypsin DeficiencyGastroenterology, 2024
- Fazirsiran for Adults With Alpha-1 Antitrypsin Deficiency Liver Disease: A Phase 2 Placebo Controlled Trial (SEQUOIA)Gastroenterology, 2024
- FRI-164 Proteomic analysis identified fazirsiran treatment-responsive protein biomarkers in patients with alpha-1 antitrypsin deficiency-associated liver diseaseJournal of Hepatology, 2024
- Review article: New developments in biomarkers and clinical drug development in alpha‐1 antitrypsin deficiency‐related liver diseaseAlimentary Pharmacology & Therapeutics, 2024
- Pharmacokinetics and Pharmacodynamics of GalNAc‐Conjugated siRNAsThe Journal of Clinical Pharmacology, 2023
- Fazirsiran for Liver Disease Associated with Alpha 1 -Antitrypsin DeficiencyNew England Journal of Medicine, 2022
- Development of an RNAi therapeutic for alpha-1-antitrypsin liver diseaseJCI Insight, 2020
- Pathophysiology of Alpha-1 Antitrypsin Deficiency Liver Disease2017